|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
Two different mutations were found in 14 NSCLCs and the most frequent one was G12D and G12V (n = 8).
|
30368666 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
KRAS G12D and STK11 mutations confer poor prognoses for patients with KRAS-mutant NSCLC.
|
31200821 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
A biopsy acquired after disease progression revealed the original SDC4-ROS1 fusion along with a KRAS point mutation (p.G12D).We reviewed the related literature to determine the frequency of gene mutations in non-small cell lung cancer patients.
|
28971587 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
CLINVAR |
Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
|
26372703 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
A doxycycline-inducible mouse model of KRAS (G12D) driven NSCLC and patient data was analyzed from multiple publicly accessible databases including TCGA, CCLE, NCBI GEO and Project Achilles.
|
26173780 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
Using genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria.
|
23959381 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation.
|
22247021 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
CLINVAR |
Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.
|
22897852 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
CLINVAR |
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
|
22235099 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.
|
21169357 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
CLINVAR |
Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
|
21398618 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
CLINVAR |
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
|
20609353 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
|
19047918 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
|
19047918 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
|
17910045 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
|
19029981 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
CausalMutation
|
CLINVAR |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |